

Joachim Almquist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4667632/publications.pdf>

Version: 2024-02-01

27
papers

534
citations

933447

10
h-index

677142

22
g-index

28
all docs

28
docs citations

28
times ranked

872
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1106-1120.	2.0	5
2	A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 296-306.	5.6	18
3	Nonlinear Mixed Effects Modeling of Deterministic and Stochastic Dynamical Systems in Wolfram Mathematica. <i>IFAC-PapersOnLine</i> , 2021, 54, 409-414.	0.9	5
4	Mathematical Model Predicts that Acceleration of Diabetic Wound Healing is Dependent on Spatial Distribution of VEGF-A mRNA (AZD8601). <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 321-338.	2.1	5
5	Exposure-response modeling improves selection of radiation and radiosensitizer combinations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 49, 167.	1.8	2
6	Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials. <i>Lancet Rheumatology</i> , The, 2020, 2, e31-e41.	3.9	11
7	Model-Based Analysis Reveals a Sustained and Dose-Dependent Acceleration of Wound Healing by VEGF-A mRNA (AZD8601). <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 384-394.	2.5	4
8	Estimation of Equipotent Doses for Anti-Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor Modulator. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 444-455.	2.5	6
9	Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis. , 2020, , .		0
10	Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1159-1173.	2.3	7
11	Challenging the dose-response-time data approach: Analysis of a complex system. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 128, 250-269.	4.0	1
12	Overexpressing cell systems are a competitive option to primary adipocytes when predicting in vivo potency of dual GPR81/GPR109A agonists. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 155-165.	4.0	5
13	Model-Based Evaluation of Radiation and Radiosensitizing Agents in Oncology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 51-58.	2.5	9
14	Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics. <i>AAPS Journal</i> , 2018, 20, 88.	4.4	3
15	Evaluation and translation of combination therapies in oncology – A quantitative approach. <i>European Journal of Pharmacology</i> , 2018, 834, 327-336.	3.5	4
16	Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 203-222.	1.8	8
17	Tumor Static Concentration Curves in Combination Therapy. <i>AAPS Journal</i> , 2017, 19, 456-467.	4.4	15
18	Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1213-1222.	3.8	19

#	ARTICLE	IF	CITATIONS
19	Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 313-323.	2.5	9
20	Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 191-209.	1.8	19
21	Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats. <i>AAPS Journal</i> , 2015, 17, 586-596.	4.4	27
22	A Nonlinear Mixed Effects Approach for Modeling the Cell-To-Cell Variability of Mig1 Dynamics in Yeast. <i>PLoS ONE</i> , 2015, 10, e0124050.	2.5	25
23	Yeast AMP-activated Protein Kinase Monitors Glucose Concentration Changes and Absolute Glucose Levels. <i>Journal of Biological Chemistry</i> , 2014, 289, 12863-12875.	3.4	38
24	Joint Feedback Analysis Modeling of Nonesterified Fatty Acids in Obese Zucker Rats and Normal Sprague-Dawley Rats after Different Routes of Administration of Nicotinic Acid. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 2571-2584.	3.3	4
25	Kinetic models in industrial biotechnology – Improving cell factory performance. <i>Metabolic Engineering</i> , 2014, 24, 38-60.	7.0	238
26	Bridging the gaps in systems biology. <i>Molecular Genetics and Genomics</i> , 2014, 289, 727-734.	2.1	38
27	Modeling the Effect of Kv1.5 Block on the Canine Action Potential. <i>Biophysical Journal</i> , 2010, 99, 2726-2736.	0.5	9